Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Prostate cancer is the most common cancer in men. Its incidence is rising as the population ages. In the localized stage, the 5-year overall survival rate (OS) is 98%. Metastatic progression and resistance to castration have a negative impact on prognosis. Despite recent advances in management, the 5-year OS is around 30%. Therapeutic advances in this indication have been made mainly by the use of taxanes and second-generation hormone therapy. These treatments have improved OS and progression-free survival (PFS). They are now used as standard therapy. More recently, the Phase III VISION trial

Trial Details

NCT ID
NCT06600802
Phase
NA
Sponsor
Centre Jean Perrin
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Blood samples
Locations (sample)
  • Clermont-Ferrand, France|45.77969,3.08682
  • La Tronche, France|45.20507,5.74629
  • Pierre-Bénite, France|45.70359,4.82424
  • Saint-Etienne, France|45.43389,4.39
  • Strasbourg, France|48.58392,7.74553

Key Eligibility Criteria

  • Male \>18 years of age
  • Patient with histologically confirmed of metastatic castration resistant prostatic adenocarcinoma and with tumor biological material available (pro…
  • Patient who received at least one taxane line and a second generation hormone therapy line
  • Patient receiving androgen deprivation therapy with serum testosterone \< 50 ng/dL or \< 1.7 nmol/L or having undergone surgical castration

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →